Pharmacologic treatment options for prediabetes

被引：0
|
作者：
Willa A Hsueh
Yehuda Handelsman
机构：
[1] Obesity and Lipids,WA Hsueh is the Director of the Diabetes Research Center and Chief of the Division of Diabetes
[2] Methodist Hospital Research Institute,undefined
[3] Houston,undefined
[4] TX,undefined
[5] USA,undefined
[6] Y Handelsman is the Medical Director of the Metabolic Institute of America,undefined
[7] Tarzana,undefined
[8] CA,undefined
[9] USA.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2008年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Identification and subsequent treatment of individuals with prediabetes can prevent progression to type 2 diabetes mellitus. Although lifestyle changes are critical in this setting, the question of whether pharmacotherapy should also be used remains unanswered. The authors of this Viewpoint, therefore, discuss potential strategies for pharmacologic intervention.
引用
收藏
页码：380 / 381
页数：1
相关论文
共 50 条
12345